secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2026-09-08T13:15:54+00:00
Accession:  0001140361-26-035859
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant's mosliciguat hits all PHocus endpoints: PVR -56.3%, 6MWD +35.2m in PH-ILD
--------------------------------------------------------------------------------

- PHocus Phase 2 met primary endpoint: placebo-adjusted PVR reduction -56.3% (p<0.0001) at Week 16 in PH-ILD
- Secondary endpoints met: 6MWD +35.2m (p=0.0027), NT-proBNP -53.2% (p=0.0002) at Week 16
- Week 24 exploratory: 6MWD +52.7m, NT-proBNP -75.9% (both nominal p<0.0001)
- Cough lower than placebo (12.1% vs 18.2%); favorable safety profile
- Phase 3 PHrontier initiated (~375 patients); results presented at ERS 2026

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/0001140361-26-035859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/ef20081686_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-035859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer